In the starkest opposition yet by Republicans to the Trump administration’s attacks on HHS agencies, senators from both parties sounded an alarm about the damage being done to biomedical research in the U.S.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
